Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma-Reference-Cited by-同舟云学术

Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma

Published:2015-08-11 Issue:6 Volume:8 Page:373-383
ISSN:1756-2848
Container-title:Therapeutic Advances in Gastroenterology
language:en
Short-container-title:Therap Adv Gastroenterol

Author:

Young Kate¹,Smyth Elizabeth¹,Chau Ian²

Affiliation:

1. Royal Marsden Hospital, Gastrointestinal Oncology Unit, Sutton, Surrey, UK

2. Royal Marsden Hospital, Gastrointestinal Oncology Unit, Down’s Road, Sutton, Surrey SM2 5PT, UK

Abstract

Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.

Publisher

SAGE Publications

Subject

Gastroenterology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1756283X15592586

Reference24 articles.

1. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)

2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

3. Comprehensive molecular characterization of gastric adenocarcinoma

4. VEGFA and tumour angiogenesis

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the MET Gene: Doublet Treatment versus Single Agent Treatment;International Journal of Molecular Sciences;2024-02-01

2. Decoding the expression pattern of MUC3A in gastric adenocarcinoma: unveiling the key to successful immunotherapy;Expert Opinion on Therapeutic Targets;2023-12-02

3. Gastric Cancer: Molecular Mechanisms, Novel Targets, and Immunotherapies: From Bench to Clinical Therapeutics;Cancers;2023-10-20

4. INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG);BMC Cancer;2023-02-22

5. Molecular targeted therapy for anticancer treatment;Experimental & Molecular Medicine;2022-10-12